Output details

Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1

To engineer successful drug delivery vectors, their blood compatibility must first be understood. The discovery of the blood-binding mechanism of anti-cancer agent adenovirus is described here in the leading heamatology journal. Consequently, pre-clinical testing and clinical administration of adenovirus changed, and the MHRA removed requirement for testing in macaques. Selected for oral presentation 2008; British Society of Gene and Cell Therapy and Gene Delivery Symposium (Cold Spring Harbour). Prize-winning poster, European Society of Gene and Cell Therapy, 2008. Featured during educational session (American Society Gene and Cell Therapy, P.Ng 2011). Led to further programme funding (CRUKC552/A11339) and publication (JCR, 2009).